Even with tight T2T, ARCTIC 10yr follow-up (n=170) show 9% had RA-ILD on HRCT, plus another 19% with non-specific interstitial findings. Male sex and older age were risk factors. Seropositivity was not. Vigilance remains essential. @RheumNow #EULAR2026 POS1270

#EULAR2026 Recommendations: Vasculitis -Confirm diagnosis with imaging and biopsy - Start GC early but with taper plan - For major flare again confirm dx and restart GC - Consider IL-6 or UPA - MTX may be option if biologics not available @RheumNow https://t.co/DqLZtW630y

• https://x.com/JihaRheum/status/2063174271061344591/photo/1

#EULAR2026 POS1355 A cohort study in Japan identified 5-score predictors of GC-free remission in #lupusnephritis: HCQ, pulsed IV GC, Chronicity index=0, =>75% UPCR reduction by 6mo,& 12 mths CRR. Data cutoff 2024. Interested to see impact of current Combo tx from outset @RheumNow https://t.co/qmpgyEyOOV

• https://x.com/Yuz6Yusof/status/2063192348499034168/photo/1

Core definitions when understanding vaccination. @RheumNow #EULAR2026 https://t.co/wD0iTDxMEx

• https://x.com/RHEUMarampa/status/2063177556216439274/photo/1

RheumNow’s expanded coverage of #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA? Over 70% of patients with psoriatic arthritis (PsA) struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. https://t.co/pAIXkdazci https://t.co/vQTn3BWv2r

• Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA? | RheumNow

CT imaging in RA Body composition changes beyond BMI 489 RA vs 397 ctrl RA asso w/ -increased subcutaneous fat -increased intermuscular adipose tissue -poorer muscle quality Looks like it represent “hidden obesity” with more by fat redistribution and myosteatosis #OP0348

And now does MRI do better than US at predicting RA progression in at risk pts? Short answer: No likely too sensitive! 130 anti-CCP+ symptomatic pts 36.9% progressed BL US positivity predicted progression HR 2.8 MRI showed prevalence of subclinical disease synovitis >80%

Do probiotics help in #PsA? First RCT (MEDIPSA) says no. Multispecies probiotic vs placebo in 66 pts: 43% vs 65% achieved low disease activity at wk 12 (p=0.167). Gut-joint axis intriguing, but probiotics not the answer yet. @RheumNow #EULAR2026 POS0290

"It takes about a million dollars to get one AI algorithm approved" So even after creating an Ai solution, its difficult to actually be able to use it in rheumatology. @RheumNow #EULAR2026 https://t.co/yX6cT19Sdd

• https://x.com/bella_mehta/status/2062906379350770122/photo/1

Detecting subclinica tenosynovitis in pts at risk for RA: who does it better US or DixonMRI? 65 pts RA CSA, US detected only ~23% of cases identified by Dixon US misses most! But are they “real” tenosynovitis? MRI (5-min, no contrast) higher sens US higher spe Shall we do https://t.co/stsMRdj9eY

• https://x.com/AurelieRheumo/status/2062946900035203290/photo/1

What does remission really mean to patients with #PsA? The RemiPPsA international qualitative study asked 123 patients across 11 countries. Pain-free + ability to resume daily life topped the list, not just composite scores. #EULAR2026 @RheumNow, POS0294 https://t.co/mEGpkewuTX

• https://x.com/JihaRheum/status/2062888670106161256/photo/1

#EULAR2026 POS0172 #Lupus arthritis is the most common domain in RCTs but SLEDAI-MSK or BILAG-MSK isn’t satisfactory. Look out for the role out of LAMDA once externally validated using independent trial datasets. 4 candidates: SJC28, ESR, VAS Phy MSK, & VAS Pa Pain @RheumNow https://t.co/QJ51ETLSSN

• https://x.com/Yuz6Yusof/status/2062889577862344849/photo/1